Insilico's AI-Designed Drug Reaches Phase III
Rentosertib treats idiopathic pulmonary fibrosis, a disease that destroys lung tissue with no truly effective treatment available today. This isn't AI just screening existing molecules: it identified the target and designed the drug itself, start to finish. Two years after their partnership with Takeda on other targets, Insilico is now pushing its own candidates all the way through.
practitioners › Rentosertib (formerly ISM001-055) targets the TNIK protein, Phase III launched July 7, 2026, Insilico Medicine.
Insilico Medicine →